Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment

The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the sur...

Full description

Saved in:
Bibliographic Details
Published inCirculation research Vol. 132; no. 10; pp. 1320 - 1337
Main Author Chappell, Mark C.
Format Journal Article
LanguageEnglish
Published United States Lippincott Williams & Wilkins 12.05.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1–7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1–7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT 1 AT 2 and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.
AbstractList The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1–7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1–7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT 1 AT 2 and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.
The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT AT and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.
The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT1 AT2 and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT1 AT2 and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.
Author Chappell, Mark C.
AuthorAffiliation Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC
AuthorAffiliation_xml – name: Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC
Author_xml – sequence: 1
  givenname: Mark C.
  surname: Chappell
  fullname: Chappell, Mark C.
  organization: Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37167353$$D View this record in MEDLINE/PubMed
BookMark eNqFUUtv1DAQtlAR3RZ-AihHLllm_Eg2cEBR2tKVKq20C1wtJ5l0DYnT2llK_3292lIeF-bi0cz3GPk7YUdudMTYa4Q5YobvquW6Wp9vystyjlzMBcfFQjxjM1RcplLleMRmAFCkuRBwzE5C-AaAUvDiBTsWOWa5UGLGVmty1qWlu7bjRC5Yl2zuw0RDYlybbOhncma7jjy5hkISt9Xq6_IsxeJ9UiaVt5NtTJ-UIVAIA7npJXvemT7Qq8f3lH25OP9cXaZXq0_LqrxKG8VFlhpljCpI1TmHfME7DtAZAFnXRbxRcmpk26ISLclc1FKRik0BRLJR0nQLcco-HnRvdvVAbROtven1jbeD8fd6NFb_vXF2q6_HHxoBcxSIUeHto4Ifb3cUJj3Y0FDfG0fjLmi-QKFiQRahb_40e3L59Y0RoA6Axo8heOqeIAh6H5f-HZeOcelDXJH34R9eYycz2XF_s-3_y5YH9t3YT-TD9353R15vyfTTVsfwQQDylAMXoJBDuh9l4gEkzqnj
CitedBy_id crossref_primary_10_1016_j_semerg_2023_102187
crossref_primary_10_1186_s10020_024_00855_2
crossref_primary_10_1021_acs_analchem_4c05172
crossref_primary_10_1161_CIRCRESAHA_123_322935
crossref_primary_10_1016_j_bbi_2024_03_037
crossref_primary_10_1186_s13054_023_04739_5
crossref_primary_10_1016_j_compbiomed_2024_109631
crossref_primary_10_1016_j_peptides_2024_171201
crossref_primary_10_1152_ajplung_00372_2024
crossref_primary_10_1007_s10528_024_10813_6
crossref_primary_10_1248_bpb_b23_00568
crossref_primary_10_3390_ijms25189960
crossref_primary_10_1016_j_cophys_2023_100704
crossref_primary_10_1021_acsptsci_4c00120
crossref_primary_10_1007_s11357_024_01487_4
crossref_primary_10_1186_s13054_024_05123_7
Cites_doi 10.1001/jama.2022.15454
10.3389/fimmu.2022.1055811
10.1002/rmv.2223
10.3389/fimmu.2018.00794
10.1038/s41598-022-24628-1
10.1183/13993003.03730-2020
10.1124/pharmrev.120.000281
10.1001/jamanetworkopen.2022.7852
10.1152/physrev.00023.2016
10.1161/CIRCULATIONAHA.116.022385
10.1186/s40249-020-00662-x
10.3390/ijms23137209
10.1016/j.eururo.2015.01.027
10.1038/s41591-022-01840-0
10.1016/j.jpeds.2018.09.058
10.3390/ijms231810968
10.1001/jamainternmed.2022.2476
10.1016/j.isci.2021.102254
10.1016/j.cjco.2021.05.007
10.1080/22221751.2021.1969869
10.1002/hsr2.1011
10.1007/s10456-021-09823-4
10.1186/s12916-020-01851-z
10.1161/HYPERTENSIONAHA.113.01648
10.1016/0022-4731(89)90084-8
10.1016/j.jmii.2022.10.003
10.1093/eurjpc/zwaa155
10.1164/rccm.202106-1514OC
10.1016/j.euf.2020.05.009
10.1177/1087057111413919
10.3390/jcm11247314
10.1164/rccm.202108-1904ED
10.1042/CS20171550
10.1371/journal.pone.0198144
10.1183/23120541.00114-2021
10.1530/JOE-20-0260
10.1038/s41586-022-04479-6
10.1016/j.omtm.2022.07.003
10.1152/physiol.00035.2018
10.1002/jmv.27144
10.1097/CCM.0000000000005589
10.1161/HYPERTENSIONAHA.120.16724
10.1016/j.celrep.2020.108485
10.1183/23120541.00848-2020
10.1038/ki.2013.518
10.1161/CIRCRESAHA.116.303587
10.1152/ajprenal.00677.2013
10.7150/ijms.46695
10.1152/ajpheart.00897.2014
10.1161/CIRCRESAHA.120.317015
10.1038/s41598-021-95308-9
10.1152/ajpregu.1997.273.6.R1908
10.3390/ijms23020927
10.3389/fcvm.2022.847809
10.1038/s41588-020-00759-x
10.1128/spectrum.02362-21
10.3389/fimmu.2020.564526
10.1042/BJ20040634
10.1016/j.cell.2020.04.035
10.1161/HYPERTENSIONAHA.121.18295
10.1093/ehjcvp/pvaa138
10.3390/v15010167
10.1152/ajplung.00129.2021
10.1038/s41562-022-01450-3
10.1128/JVI.00964-21
10.1097/00004872-199606000-00017
10.3389/fcvm.2021.710946
10.3390/ijms21217943
10.1001/jama.2023.3546
10.1002/rmv.2395
10.3389/fcvm.2022.869251
10.1089/andro.2022.0006
10.1136/bmjopen-2021-053032
10.1152/ajpheart.00618.2015
10.1111/andr.12836
10.1152/ajplung.00498.2016
10.1016/j.hlc.2020.11.008
10.3390/cells1010275
10.1016/j.eclinm.2021.101152
10.3389/fendo.2013.00201
10.1038/s41577-021-00662-4
10.1002/jmv.27592
10.1161/01.RES.0000223145.74217.e7
10.1177/1074248417691136
10.1016/S0140-6736(20)31964-4
10.1001/jama.2023.4480
10.1016/j.mce.2022.111775
10.1080/08830185.2022.2089666
10.1164/rccm.202012-4461OC
10.1124/pharmrev.120.000236
10.1038/s41371-022-00771-0
10.1016/j.cell.2020.02.052
10.1186/s13054-020-02862-1
10.1161/HYPERTENSIONAHA.119.14071
10.1016/j.cellimm.2015.02.004
10.1016/j.jtauto.2021.100100
10.1161/CIRCRESAHA.113.300752
10.1038/s41598-021-03181-3
10.1152/ajpheart.00217.2020
10.1016/j.ahj.2021.11.016
10.1016/j.jcv.2020.104392
10.1038/s41586-020-2700-3
10.1177/1753944715597623
10.1016/S0140-6736(19)32317-7
10.1016/j.eclinm.2022.101619
10.1161/HYPERTENSIONAHA.108.114058
10.3317/jraas.2006.015
10.3389/fmed.2020.563893
10.1038/s41598-022-13585-4
10.1001/jamanetworkopen.2022.2735
10.3390/diagnostics12051124
10.1016/j.jaut.2021.102683
10.1016/s0895-7061(97)00400-7
10.1007/s11427-020-1643-8
10.1210/en.2008-1664
10.3389/fimmu.2022.981532
10.1126/sciadv.abn3777
10.1111/bph.13044
10.1016/j.eururo.2021.12.013
10.3389/fcvm.2022.809997
10.1093/ajh/hpaa169
10.1161/JAHA.118.011179
10.1001/jamanetworkopen.2021.11398
10.1161/HYPERTENSIONAHA.120.11941
10.1128/mBio.00974-21
10.1016/j.isci.2022.105748
10.1177/0961203320904787
10.1097/MD.0000000000027072
10.1152/ajpregu.00356.2020
10.3389/fimmu.2022.1028613
10.1186/ar3012
10.1164/rccm.201911-2172OC
10.1371/journal.pone.0250774
10.1016/S0140-6736(20)31561-0
10.1126/science.abb2762
10.1038/s41371-020-0335-3
10.3389/fimmu.2021.684142
10.1723/3148.31294
10.3389/fphys.2022.1080837
10.1038/s41577-021-00634-8
10.1113/expphysiol.2007.040352
10.1038/s41591-020-01227-z
10.1038/s41598-021-03731-9
10.22037/uj.v18i.6691
10.1177/17534666221122544
10.1016/j.bcp.2022.115347
10.1183/16000617.0017-2018
10.26355/eurrev_202110_26865
10.3389/fimmu.2021.756262
10.1152/ajpheart.01277.2007
10.1164/rccm.202001-0179LE
10.4172/2576-1471.1000134
10.1186/ar3052
10.1016/j.tcm.2021.09.009
10.1038/s41598-021-95565-8
10.1038/s41574-022-00780-6
10.7554/eLife.73522
10.1172/jci.insight.158362
10.1016/j.phrs.2021.105924
10.1016/j.bcp.2022.115200
10.1016/j.bcp.2022.115370
10.15252/msb.20209610
10.1186/s12916-022-02345-w
10.1136/annrheumdis-2021-222088
10.3389/fimmu.2021.625732
10.1001/jama.2020.24865
10.1038/s41467-022-28905-5
10.1038/s41591-022-01689-3
10.1016/j.jacc.2022.06.008
10.1161/01.HYP.0000085210.66399.A3
10.1152/ajpheart.00755.2020
10.1038/s41586-022-04474-x
10.3389/fendo.2021.694083
10.1016/j.autrev.2021.102754
10.3389/fendo.2022.940675
ContentType Journal Article
Copyright Lippincott Williams & Wilkins
2023 American Heart Association, Inc. 2023
Copyright_xml – notice: Lippincott Williams & Wilkins
– notice: 2023 American Heart Association, Inc. 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1161/CIRCRESAHA.123.321883
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4571
EndPage 1337
ExternalDocumentID PMC10171311
37167353
10_1161_CIRCRESAHA_123_321883
00003012-202305120-00006
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GroupedDBID ---
-~X
.-D
.3C
.Z2
01R
0R~
18M
1J1
29B
2WC
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACNWC
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADGGA
ADHPY
AE3
AE6
AENEX
AFBFQ
AFDTB
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BAWUL
BOYCO
BQLVK
C45
CS3
DIK
DIWNM
DU5
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
GNXGY
GQDEL
GX1
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
O9-
OAG
OAH
OB2
OK1
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OWW
OWY
OXXIT
P2P
PQQKQ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
YFH
YOC
ZFV
AAYXX
CITATION
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADSXY
ID FETCH-LOGICAL-c5236-a5aa59e5b720782f200fa004bb914342ec4dd153de473b45e5e4790ee4c54af83
ISSN 0009-7330
1524-4571
IngestDate Thu Aug 21 18:36:46 EDT 2025
Thu Jul 10 17:41:12 EDT 2025
Thu Apr 03 07:07:17 EDT 2025
Tue Jul 01 04:10:55 EDT 2025
Thu Apr 24 23:09:23 EDT 2025
Fri May 16 04:11:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords SARS-CoV-2
androgen
estrogen
peptidyl-dipeptidase A
angiotensin-converting enzyme 2
renin-angiotensin system
Language English
License This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c5236-a5aa59e5b720782f200fa004bb914342ec4dd153de473b45e5e4790ee4c54af83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5869-6037
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC10171311
PMID 37167353
PQID 2813555506
PQPubID 23479
PageCount 18
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10171311
proquest_miscellaneous_2813555506
pubmed_primary_37167353
crossref_primary_10_1161_CIRCRESAHA_123_321883
crossref_citationtrail_10_1161_CIRCRESAHA_123_321883
wolterskluwer_health_00003012-202305120-00006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-May-12
2023-05-12
20230512
PublicationDateYYYYMMDD 2023-05-12
PublicationDate_xml – month: 05
  year: 2023
  text: 2023-May-12
  day: 12
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hagerstown, MD
PublicationTitle Circulation research
PublicationTitleAlternate Circ Res
PublicationYear 2023
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References e_1_3_3_96_2
e_1_3_3_50_2
e_1_3_3_77_2
e_1_3_3_117_2
e_1_3_3_159_2
e_1_3_3_16_2
e_1_3_3_39_2
e_1_3_3_132_2
e_1_3_3_155_2
e_1_3_3_12_2
e_1_3_3_58_2
e_1_3_3_35_2
e_1_3_3_92_2
e_1_3_3_113_2
e_1_3_3_136_2
e_1_3_3_151_2
e_1_3_3_174_2
e_1_3_3_54_2
e_1_3_3_31_2
e_1_3_3_73_2
e_1_3_3_61_2
e_1_3_3_88_2
e_1_3_3_150_2
e_1_3_3_5_2
e_1_3_3_128_2
e_1_3_3_105_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_109_2
e_1_3_3_166_2
e_1_3_3_23_2
e_1_3_3_69_2
e_1_3_3_120_2
e_1_3_3_46_2
e_1_3_3_80_2
e_1_3_3_147_2
e_1_3_3_162_2
e_1_3_3_65_2
e_1_3_3_124_2
e_1_3_3_42_2
e_1_3_3_84_2
e_1_3_3_101_2
e_1_3_3_143_2
e_1_3_3_76_2
e_1_3_3_99_2
e_1_3_3_161_2
e_1_3_3_139_2
e_1_3_3_116_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_131_2
e_1_3_3_177_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_57_2
e_1_3_3_91_2
e_1_3_3_158_2
e_1_3_3_135_2
e_1_3_3_173_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_53_2
e_1_3_3_72_2
e_1_3_3_95_2
e_1_3_3_112_2
e_1_3_3_154_2
e_1_3_3_60_2
e_1_3_3_87_2
e_1_3_3_172_2
e_1_3_3_8_2
e_1_3_3_104_2
e_1_3_3_127_2
e_1_3_3_49_2
e_1_3_3_108_2
e_1_3_3_142_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_68_2
e_1_3_3_146_2
e_1_3_3_169_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
e_1_3_3_64_2
e_1_3_3_83_2
e_1_3_3_100_2
e_1_3_3_123_2
e_1_3_3_165_2
e_1_3_3_75_2
e_1_3_3_71_2
e_1_3_3_160_2
e_1_3_3_98_2
e_1_3_3_79_2
e_1_3_3_115_2
e_1_3_3_138_2
e_1_3_3_119_2
e_1_3_3_18_2
e_1_3_3_37_2
e_1_3_3_90_2
e_1_3_3_130_2
e_1_3_3_157_2
e_1_3_3_14_2
e_1_3_3_56_2
e_1_3_3_33_2
e_1_3_3_94_2
e_1_3_3_111_2
e_1_3_3_134_2
e_1_3_3_153_2
e_1_3_3_176_2
e_1_3_3_10_2
e_1_3_3_52_2
e_1_3_3_40_2
e_1_3_3_86_2
e_1_3_3_171_2
e_1_3_3_107_2
e_1_3_3_7_2
e_1_3_3_126_2
e_1_3_3_149_2
e_1_3_3_29_2
e_1_3_3_48_2
e_1_3_3_145_2
e_1_3_3_141_2
e_1_3_3_168_2
e_1_3_3_25_2
e_1_3_3_67_2
e_1_3_3_44_2
e_1_3_3_82_2
e_1_3_3_103_2
e_1_3_3_164_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_63_2
e_1_3_3_122_2
e_1_3_3_51_2
e_1_3_3_74_2
e_1_3_3_97_2
e_1_3_3_70_2
e_1_3_3_78_2
e_1_3_3_118_2
e_1_3_3_137_2
e_1_3_3_17_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_59_2
e_1_3_3_110_2
e_1_3_3_156_2
e_1_3_3_32_2
e_1_3_3_55_2
e_1_3_3_93_2
e_1_3_3_114_2
e_1_3_3_152_2
e_1_3_3_133_2
e_1_3_3_175_2
e_1_3_3_62_2
e_1_3_3_85_2
e_1_3_3_170_2
e_1_3_3_89_2
e_1_3_3_6_2
e_1_3_3_106_2
e_1_3_3_129_2
e_1_3_3_28_2
e_1_3_3_148_2
e_1_3_3_24_2
e_1_3_3_47_2
e_1_3_3_121_2
e_1_3_3_144_2
e_1_3_3_167_2
e_1_3_3_140_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_66_2
e_1_3_3_81_2
e_1_3_3_102_2
e_1_3_3_125_2
e_1_3_3_163_2
References_xml – ident: e_1_3_3_5_2
  doi: 10.1001/jama.2022.15454
– ident: e_1_3_3_176_2
  doi: 10.3389/fimmu.2022.1055811
– ident: e_1_3_3_6_2
  doi: 10.1002/rmv.2223
– ident: e_1_3_3_154_2
  doi: 10.3389/fimmu.2018.00794
– ident: e_1_3_3_57_2
  doi: 10.1038/s41598-022-24628-1
– ident: e_1_3_3_59_2
  doi: 10.1183/13993003.03730-2020
– ident: e_1_3_3_48_2
  doi: 10.1124/pharmrev.120.000281
– ident: e_1_3_3_134_2
  doi: 10.1001/jamanetworkopen.2022.7852
– ident: e_1_3_3_21_2
  doi: 10.1152/physrev.00023.2016
– ident: e_1_3_3_90_2
  doi: 10.1161/CIRCULATIONAHA.116.022385
– ident: e_1_3_3_39_2
  doi: 10.1186/s40249-020-00662-x
– ident: e_1_3_3_167_2
  doi: 10.3390/ijms23137209
– ident: e_1_3_3_132_2
  doi: 10.1016/j.eururo.2015.01.027
– ident: e_1_3_3_7_2
  doi: 10.1038/s41591-022-01840-0
– ident: e_1_3_3_45_2
  doi: 10.1016/j.jpeds.2018.09.058
– ident: e_1_3_3_158_2
  doi: 10.3390/ijms231810968
– ident: e_1_3_3_3_2
  doi: 10.1001/jamainternmed.2022.2476
– ident: e_1_3_3_130_2
  doi: 10.1016/j.isci.2021.102254
– ident: e_1_3_3_144_2
  doi: 10.1016/j.cjco.2021.05.007
– ident: e_1_3_3_108_2
  doi: 10.1080/22221751.2021.1969869
– ident: e_1_3_3_142_2
  doi: 10.1002/hsr2.1011
– ident: e_1_3_3_66_2
  doi: 10.1007/s10456-021-09823-4
– ident: e_1_3_3_27_2
  doi: 10.1186/s12916-020-01851-z
– ident: e_1_3_3_91_2
  doi: 10.1161/HYPERTENSIONAHA.113.01648
– ident: e_1_3_3_151_2
  doi: 10.1016/0022-4731(89)90084-8
– ident: e_1_3_3_10_2
  doi: 10.1016/j.jmii.2022.10.003
– ident: e_1_3_3_8_2
  doi: 10.1093/eurjpc/zwaa155
– ident: e_1_3_3_67_2
  doi: 10.1164/rccm.202106-1514OC
– ident: e_1_3_3_149_2
  doi: 10.1016/j.euf.2020.05.009
– ident: e_1_3_3_101_2
  doi: 10.1177/1087057111413919
– ident: e_1_3_3_166_2
  doi: 10.3390/jcm11247314
– ident: e_1_3_3_55_2
  doi: 10.1164/rccm.202108-1904ED
– ident: e_1_3_3_44_2
  doi: 10.1042/CS20171550
– ident: e_1_3_3_121_2
  doi: 10.1371/journal.pone.0198144
– ident: e_1_3_3_61_2
  doi: 10.1183/23120541.00114-2021
– ident: e_1_3_3_141_2
  doi: 10.1530/JOE-20-0260
– ident: e_1_3_3_36_2
  doi: 10.1038/s41586-022-04479-6
– ident: e_1_3_3_71_2
  doi: 10.1016/j.omtm.2022.07.003
– ident: e_1_3_3_113_2
  doi: 10.1152/physiol.00035.2018
– ident: e_1_3_3_58_2
  doi: 10.1002/jmv.27144
– ident: e_1_3_3_83_2
  doi: 10.1097/CCM.0000000000005589
– ident: e_1_3_3_73_2
  doi: 10.1161/HYPERTENSIONAHA.120.16724
– ident: e_1_3_3_156_2
  doi: 10.1016/j.celrep.2020.108485
– ident: e_1_3_3_62_2
  doi: 10.1183/23120541.00848-2020
– ident: e_1_3_3_117_2
  doi: 10.1038/ki.2013.518
– ident: e_1_3_3_22_2
  doi: 10.1161/CIRCRESAHA.116.303587
– ident: e_1_3_3_114_2
  doi: 10.1152/ajprenal.00677.2013
– ident: e_1_3_3_40_2
  doi: 10.7150/ijms.46695
– ident: e_1_3_3_119_2
  doi: 10.1152/ajpheart.00897.2014
– ident: e_1_3_3_14_2
  doi: 10.1161/CIRCRESAHA.120.317015
– ident: e_1_3_3_77_2
  doi: 10.1038/s41598-021-95308-9
– ident: e_1_3_3_112_2
  doi: 10.1152/ajpregu.1997.273.6.R1908
– ident: e_1_3_3_94_2
  doi: 10.3390/ijms23020927
– ident: e_1_3_3_69_2
  doi: 10.3389/fcvm.2022.847809
– ident: e_1_3_3_78_2
  doi: 10.1038/s41588-020-00759-x
– ident: e_1_3_3_175_2
  doi: 10.1128/spectrum.02362-21
– ident: e_1_3_3_97_2
  doi: 10.3389/fimmu.2020.564526
– ident: e_1_3_3_49_2
  doi: 10.1042/BJ20040634
– ident: e_1_3_3_42_2
  doi: 10.1016/j.cell.2020.04.035
– ident: e_1_3_3_26_2
  doi: 10.1161/HYPERTENSIONAHA.121.18295
– ident: e_1_3_3_82_2
  doi: 10.1093/ehjcvp/pvaa138
– ident: e_1_3_3_35_2
  doi: 10.3390/v15010167
– ident: e_1_3_3_54_2
  doi: 10.1152/ajplung.00129.2021
– ident: e_1_3_3_2_2
  doi: 10.1038/s41562-022-01450-3
– ident: e_1_3_3_174_2
  doi: 10.1128/JVI.00964-21
– ident: e_1_3_3_47_2
  doi: 10.1097/00004872-199606000-00017
– ident: e_1_3_3_81_2
  doi: 10.3389/fcvm.2021.710946
– ident: e_1_3_3_150_2
  doi: 10.3390/ijms21217943
– ident: e_1_3_3_126_2
  doi: 10.1001/jama.2023.3546
– ident: e_1_3_3_140_2
  doi: 10.1002/rmv.2395
– ident: e_1_3_3_147_2
  doi: 10.3389/fcvm.2022.869251
– ident: e_1_3_3_31_2
  doi: 10.1089/andro.2022.0006
– ident: e_1_3_3_162_2
  doi: 10.1136/bmjopen-2021-053032
– ident: e_1_3_3_17_2
  doi: 10.1152/ajpheart.00618.2015
– ident: e_1_3_3_28_2
  doi: 10.1111/andr.12836
– ident: e_1_3_3_51_2
  doi: 10.1152/ajplung.00498.2016
– ident: e_1_3_3_52_2
  doi: 10.1016/j.hlc.2020.11.008
– ident: e_1_3_3_63_2
  doi: 10.3390/cells1010275
– ident: e_1_3_3_84_2
  doi: 10.1016/j.eclinm.2021.101152
– ident: e_1_3_3_18_2
  doi: 10.3389/fendo.2013.00201
– ident: e_1_3_3_165_2
  doi: 10.1038/s41577-021-00662-4
– ident: e_1_3_3_87_2
  doi: 10.1002/jmv.27592
– ident: e_1_3_3_123_2
  doi: 10.1161/01.RES.0000223145.74217.e7
– ident: e_1_3_3_146_2
  doi: 10.1177/1074248417691136
– ident: e_1_3_3_122_2
  doi: 10.1016/S0140-6736(20)31964-4
– ident: e_1_3_3_129_2
  doi: 10.1001/jama.2023.4480
– ident: e_1_3_3_164_2
  doi: 10.1016/j.mce.2022.111775
– ident: e_1_3_3_177_2
  doi: 10.1080/08830185.2022.2089666
– ident: e_1_3_3_56_2
  doi: 10.1164/rccm.202012-4461OC
– ident: e_1_3_3_75_2
  doi: 10.1124/pharmrev.120.000236
– ident: e_1_3_3_115_2
  doi: 10.1038/s41371-022-00771-0
– ident: e_1_3_3_15_2
  doi: 10.1016/j.cell.2020.02.052
– ident: e_1_3_3_88_2
  doi: 10.1186/s13054-020-02862-1
– ident: e_1_3_3_124_2
  doi: 10.1161/HYPERTENSIONAHA.119.14071
– ident: e_1_3_3_25_2
  doi: 10.1016/j.cellimm.2015.02.004
– ident: e_1_3_3_168_2
  doi: 10.1016/j.jtauto.2021.100100
– ident: e_1_3_3_105_2
  doi: 10.1161/CIRCRESAHA.113.300752
– ident: e_1_3_3_13_2
  doi: 10.1038/s41598-021-03181-3
– ident: e_1_3_3_16_2
  doi: 10.1152/ajpheart.00217.2020
– ident: e_1_3_3_143_2
  doi: 10.1016/j.ahj.2021.11.016
– ident: e_1_3_3_12_2
  doi: 10.1016/j.jcv.2020.104392
– ident: e_1_3_3_137_2
  doi: 10.1038/s41586-020-2700-3
– ident: e_1_3_3_20_2
  doi: 10.1177/1753944715597623
– ident: e_1_3_3_86_2
– ident: e_1_3_3_23_2
  doi: 10.1016/S0140-6736(19)32317-7
– ident: e_1_3_3_170_2
  doi: 10.1016/j.eclinm.2022.101619
– ident: e_1_3_3_116_2
  doi: 10.1161/HYPERTENSIONAHA.108.114058
– ident: e_1_3_3_120_2
  doi: 10.3317/jraas.2006.015
– ident: e_1_3_3_148_2
  doi: 10.3389/fmed.2020.563893
– ident: e_1_3_3_161_2
  doi: 10.1038/s41598-022-13585-4
– ident: e_1_3_3_80_2
  doi: 10.1001/jamanetworkopen.2022.2735
– ident: e_1_3_3_74_2
  doi: 10.3390/diagnostics12051124
– ident: e_1_3_3_98_2
  doi: 10.1016/j.jaut.2021.102683
– ident: e_1_3_3_46_2
  doi: 10.1016/s0895-7061(97)00400-7
– ident: e_1_3_3_70_2
  doi: 10.1007/s11427-020-1643-8
– ident: e_1_3_3_111_2
  doi: 10.1210/en.2008-1664
– ident: e_1_3_3_99_2
  doi: 10.3389/fimmu.2022.981532
– ident: e_1_3_3_103_2
  doi: 10.1126/sciadv.abn3777
– ident: e_1_3_3_85_2
  doi: 10.1111/bph.13044
– ident: e_1_3_3_133_2
  doi: 10.1016/j.eururo.2021.12.013
– ident: e_1_3_3_29_2
  doi: 10.3389/fcvm.2022.809997
– ident: e_1_3_3_60_2
  doi: 10.1093/ajh/hpaa169
– ident: e_1_3_3_107_2
  doi: 10.1161/JAHA.118.011179
– ident: e_1_3_3_153_2
  doi: 10.1001/jamanetworkopen.2021.11398
– ident: e_1_3_3_118_2
  doi: 10.1161/HYPERTENSIONAHA.120.11941
– ident: e_1_3_3_163_2
  doi: 10.1128/mBio.00974-21
– ident: e_1_3_3_65_2
  doi: 10.1016/j.isci.2022.105748
– ident: e_1_3_3_96_2
  doi: 10.1177/0961203320904787
– ident: e_1_3_3_139_2
  doi: 10.1097/MD.0000000000027072
– ident: e_1_3_3_173_2
  doi: 10.1152/ajpregu.00356.2020
– ident: e_1_3_3_64_2
  doi: 10.3389/fimmu.2022.1028613
– ident: e_1_3_3_100_2
  doi: 10.1186/ar3012
– ident: e_1_3_3_89_2
  doi: 10.1164/rccm.201911-2172OC
– ident: e_1_3_3_160_2
  doi: 10.1371/journal.pone.0250774
– ident: e_1_3_3_30_2
  doi: 10.1016/S0140-6736(20)31561-0
– ident: e_1_3_3_34_2
  doi: 10.1126/science.abb2762
– ident: e_1_3_3_43_2
  doi: 10.1038/s41371-020-0335-3
– ident: e_1_3_3_104_2
  doi: 10.3389/fimmu.2021.684142
– ident: e_1_3_3_159_2
  doi: 10.1723/3148.31294
– ident: e_1_3_3_53_2
  doi: 10.3389/fphys.2022.1080837
– ident: e_1_3_3_50_2
  doi: 10.1038/s41577-021-00634-8
– ident: e_1_3_3_76_2
  doi: 10.1113/expphysiol.2007.040352
– ident: e_1_3_3_33_2
  doi: 10.1038/s41591-020-01227-z
– ident: e_1_3_3_79_2
  doi: 10.1038/s41598-021-03731-9
– ident: e_1_3_3_131_2
  doi: 10.22037/uj.v18i.6691
– ident: e_1_3_3_68_2
  doi: 10.1177/17534666221122544
– ident: e_1_3_3_145_2
  doi: 10.1016/j.bcp.2022.115347
– ident: e_1_3_3_125_2
  doi: 10.1183/16000617.0017-2018
– ident: e_1_3_3_135_2
  doi: 10.26355/eurrev_202110_26865
– ident: e_1_3_3_157_2
  doi: 10.3389/fimmu.2021.756262
– ident: e_1_3_3_109_2
  doi: 10.1152/ajpheart.01277.2007
– ident: e_1_3_3_41_2
  doi: 10.1164/rccm.202001-0179LE
– ident: e_1_3_3_127_2
  doi: 10.4172/2576-1471.1000134
– ident: e_1_3_3_93_2
  doi: 10.1186/ar3052
– ident: e_1_3_3_9_2
  doi: 10.1016/j.tcm.2021.09.009
– ident: e_1_3_3_11_2
  doi: 10.1038/s41598-021-95565-8
– ident: e_1_3_3_24_2
  doi: 10.1038/s41574-022-00780-6
– ident: e_1_3_3_172_2
  doi: 10.7554/eLife.73522
– ident: e_1_3_3_102_2
  doi: 10.1172/jci.insight.158362
– ident: e_1_3_3_128_2
  doi: 10.1016/j.phrs.2021.105924
– ident: e_1_3_3_155_2
  doi: 10.1016/j.bcp.2022.115200
– ident: e_1_3_3_19_2
  doi: 10.1016/j.bcp.2022.115370
– ident: e_1_3_3_38_2
  doi: 10.15252/msb.20209610
– ident: e_1_3_3_138_2
  doi: 10.1186/s12916-022-02345-w
– ident: e_1_3_3_106_2
  doi: 10.1136/annrheumdis-2021-222088
– ident: e_1_3_3_72_2
  doi: 10.3389/fimmu.2021.625732
– ident: e_1_3_3_4_2
  doi: 10.1001/jama.2020.24865
– ident: e_1_3_3_92_2
  doi: 10.1038/s41467-022-28905-5
– ident: e_1_3_3_169_2
  doi: 10.1038/s41591-022-01689-3
– ident: e_1_3_3_171_2
  doi: 10.1016/j.jacc.2022.06.008
– ident: e_1_3_3_110_2
  doi: 10.1161/01.HYP.0000085210.66399.A3
– ident: e_1_3_3_32_2
  doi: 10.1152/ajpheart.00755.2020
– ident: e_1_3_3_37_2
  doi: 10.1038/s41586-022-04474-x
– ident: e_1_3_3_136_2
  doi: 10.3389/fendo.2021.694083
– ident: e_1_3_3_95_2
  doi: 10.1016/j.autrev.2021.102754
– ident: e_1_3_3_152_2
  doi: 10.3389/fendo.2022.940675
SSID ssj0014329
Score 2.516122
SecondaryResourceType review_article
Snippet The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially...
SourceID pubmedcentral
proquest
pubmed
crossref
wolterskluwer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1320
SubjectTerms Angiotensin-Converting Enzyme 2 - metabolism
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Compendium on COVID-19 and Cardiovascular Disease
COVID-19
Female
Humans
Male
Peptidyl-Dipeptidase A - physiology
Post-Acute COVID-19 Syndrome
Renin-Angiotensin System - physiology
SARS-CoV-2
Sex Characteristics
Title Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00003012-202305120-00006
https://www.ncbi.nlm.nih.gov/pubmed/37167353
https://www.proquest.com/docview/2813555506
https://pubmed.ncbi.nlm.nih.gov/PMC10171311
Volume 132
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9NAEF_0BBFEfFtfRPCbbG321azfQryzJ-cVjlb6bckmm7Mo6XHXovjXO_tI0tCCp19C2GSTZX_Z2ZnJzG8QelvRXAtZlpgkfIRhP6Y4YSbHvCwl0VKMqXZsn6diMmefF3zRFcFz2SVrPSx-780r-R9UoQ1wtVmy_4Bs-1BogHPAF46AMByvhfGZqZc1Tuvz5coFoteBgNzHY5pfINCqkM_nwl6z6dfjjziWIR29qXKQtuyc26pqtrwsQm2vd4ESqHUd26yFi_DHwmb7BF9r8B4QF6sXk22BRxhm3JdBGZo9bY2U7NyQmzYU1Qs9m4W9XxoLK42z47MMvqZ0Yh2vdEhBqfC1a_rs16dTdTQ_OVGzw8XsJrpFQO23FSk-LdqQHVDtXNW5dnwhIwte837vS_q6xo4BsRsHe_fnysYoXH13KQpbisbsProXLIQo9XA_QDdM_RDd_hJiIB6h6Q7qkUc9AtQjQD3aQj2Cqw3qH6I0ajCPOswfo_nR4Syb4FAWAxecUIFznudcGq7HxOp3FayIKodVobWEGWLEFKwsYSMrDYOVxrjhcCJHxrCCs7xK6BN0UK9q8wxFosoZq4ysoDcbl0IzSYiMi4QyTUkpBog1E6iKwBlvS5f8UM52FLHq5l3BvCs_7wM0bLtdeNKUv3V406CjQLzZf1Z5bVabK0WSGDRiMKNhLE89Wu0jKdj6Y5AuA5T0cGxvsNTp_Sv18pujULcbkSWaGiDcg1z57GMbkmF9BQTbNQP7FnH0CyPx_BoDfYHudCvtJTpYX27MK9Bc1_q1-5z_AC6AkNw
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renin-Angiotensin+System+and+Sex+Differences+in+COVID-19%3A+A+Critical+Assessment&rft.jtitle=Circulation+research&rft.au=Chappell%2C+Mark+C&rft.date=2023-05-12&rft.issn=1524-4571&rft.eissn=1524-4571&rft.volume=132&rft.issue=10&rft.spage=1320&rft_id=info:doi/10.1161%2FCIRCRESAHA.123.321883&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7330&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7330&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7330&client=summon